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SUPPLEMENTARY NOTES
ABSTRACT
We initially identified and characterized a CD2-mediated, interleukin (IL)-12-dependent signaling pathway which inhibits apoptosis in mitogen-stimulated human γδ-T cells. We have since exploited this pathway to develop the methodologies allowing the large-scale ex vivo expansion of viable apoptosis-resistant γδ-T cells -an undertaking until now, not possible. Importantly, we have shown that apoptosis-resistant human γδ-T cells retain significant innate, major histocompatibility complex (MHC)-unrestricted cytotoxicity against a wide variety of human-derived tumor cell lines, including human breast cancer cell lines. Our efforts related to this proposal have remained focused upon testing the hypothesis that γδ-T cells -by virtue of their innate ability to recognize and kill epithelial-derived malignancies -play an important role in regulating the initial growth or spread of breast cancer in vivo. In this progress report, we discuss the findings we have made in the first year of this award. Although the human pre-clinical work is too preliminary to report at this point, we have made some important progressin optimizing our animal models to assess the ability of γδ-T cells to moderate tumor growth in a syngeneic model of breast cancer. Problems encountered in the first year -and their solutions -are discussed in this first annual report. 
I NTRODUCTI ON
We initially identified and characterized a CD2-mediated, interleukin (IL)-12-dependent signaling pathway which inhibits apoptosis in mitogen-stimulated human γδ-T cells. We have since exploited this pathway to develop the methodologies allowing the large-scale ex vivo expansion of viable apoptosis-resistant γδ-T cells -an undertaking until now, not possible. Importantly, we have shown that apoptosis-resistant human γδ-T cells retain significant innate, major histocompatibility complex (MHC)-unrestricted cytotoxicity against a wide variety of human-derived tumor cell lines, including human breast cancer cell lines. Our efforts related to this proposal have remained focused upon testing the hypothesis that γδ-T cells -by virtue of their innate ability to recognize and kill epithelial-derived malignancies -play an important role in regulating the initial growth or spread of breast cancer in vivo.
BODY
I n the ini ti al peri od of this gr ant for whi c h thi s repor t is generat ed (2 February , 2006 to 2 Februar y, 2007) our acc ompl i shments are pr es ent ed in rel ati on to the foll owi ng task s as outl i ned in the approved Stat ement of Wor k.
Task 1: Clinicopathologic correlations. To determine the extent to which γδ-T cell numbers; γδ-T cell innate antitumor capacity and γδ-T cell expansion potential vary as a function of breast cancer clinical stage, clinical progression and clinical response to standard therapy.
Task 2: Basic tumor immunobiology. To further refine our understanding of the in vitro biology (recognition and effector functions) of the antitumor cytotoxicity mediated by human γδ-T cells against human breast cancer cells.
• We have re-prioritized the order in which we are approaching our tasks. All patient-related studies or studies using human materials (patient blood or human cell lines) were moved back 12 months. As such, there are no results to be presented in this report related to Task 1 and 2. These studies are now underway and will be reported with the 2nd annual report as they are too preliminary.
Task 3: Pre-clinical models for the adoptive cellular immunotherapy of breast cancer. To determine the extent to which γδ-T cells can regulate the growth and metastasis of breast cancer cells in vivo using preclinical animal models.
1) Treatment of tumor-bearing animals with human γδ-T cells (xenograft model).
• As noted above, all studies involving the use of human materials (patient blood or human cell lines) were moved back 12 months. Studies in this sub-task are now beginning and will be reported with the 2nd annual report as they are too preliminary.
2) Mouse syngeneic breast cancer model. Tumorigenic mouse breast cancer cell line 4T1 (derived from BALB/c) have been used to establish disease in syngeneic BALB/c animals. Using two approaches (proof-of-principle studies and adoptive immunotherapy studies), we are now examining the extent to which murine gamma/delta T-cells can prevent the growth or metastasis of 4T1 cells in vivo.
1. Proof-of-principle studies. As init ial ly propos ed, we pr edi ct ed that mi ce depl et ed of γ δ-T cell s usi ng the GL3 ant i -γ δ T cell receptor (TCR) anti body woul d hav e mor e rapid di seas e progr ess ion when c hall enged wi th t umori genic 4T1 br eas t canc er cel ls . We have curr ent ly been opti mi zi ng our model by fi rs t det er mi ning empir ic all y the fewest number of t umor igeni c 4T1 cel l s to impl ant in mic e so that a pr oport ion -but not all mic e -develop tumor s . We hav e di s cover ed that thi s is key sinc e we ar e at t empt ing to det ec t what appears to be a subt le enhancement of tumor growth in mic e depleted of γ δ-T cell s . Too hi gh a tumor cel l inoc ul um appear s to mas k the eff ect s we ex pec t to see. Our ini t ial studi es -though not conc lusi ve -suggest that 4T1 cell s i mplant ed in mi ce depl et ed of γ δ-T cell s usi ng the GL3 anti -γ δ TCR ant ibody do indeed appear to gr ow f as ter, but that thi s is a very subl et ef fec t requi ri ng l ar ger number s of mi ce to ac hi ev e stati s ti cal s igni fi c ance.
Our ini t ial studi es us ing a commer ci all y av ail abl e anti -γ δ TCR ant ibody . We have noted that the cos t of the commer ci al ly av ai l able reagent has pr ov en to be prohi bit iv e-espec i al ly in studies where larger numbers of mi ce are requi red. Acc or dingl y, we have now ac qui red the hybri doma whi ch mak es the GL3 ant i body and ar e now pr oduc i ng the puri f ied ant ibody for us e in the lar ger studi es now under way . These wi ll be r epor t ed i n t he 2nd annual repor t.
2. Studies to assess immunotherapeutic potential of adoptively transferred γδ-T cells in the setting of established disease. Her e we ar e det er mi ning the ext ent to which adoptively transferred γδ-T cells can moderate growth or metastasis of established breast cancer cells. These st udies are poss ibl e as we are able to obtain γδ-T cells by direct isolation (immunomagnetic separation) from spleen cell preparations. Alternatively, we can als o isolate mous e γ δ-T cell s from s pl een cel l preparat ions fi rs t expanded i n a proc es s si mil ar to t hat used t o ex pand human γ δ-T cell s .
Howev er , we hav e di s cover ed that when lar ge numbers of γ δ-T cell s are requir ed for mul ti ple t reat ments of mul ti ple mi ce, rel iabl y gener ati ng the number of mous e γ δ-T cell s can be limi ti ng. Alt hough we can usuall y obt ai n suf fi c ient number s of γ δ-T cell s from cul tur ed spleen cell pr epar at i ons, we have real i zed that the var iat ions in the cell yi el d on ex pansi on of γ δ-T cell s from healt hy, wi ld type BALB/ c mic e can c ompromi s e our studi es.
To solv e thi s probl em, we hav e elect ed to take the appr oac h of gener at ing γ δ-T cell s from BALB/ c mic e whi ch ar e def ic ient in αβ -T cell s . This is a commonly us ed appr oach that as sures that the T cell s expanded from the spleen cell pr epar ati on ar e al l γ δ-T cell s and not contami nat ed wi th αβ -T cell s . Thi s approac h then ass ur es us that we wil l hav e a pur e popul ati on of γ δ-T cell s for adopti v e tr ans fer int o t umor -bear ing mic e. Thi s αβ -T cell defi c ient mous e on the BALB/ c bac kgr ound is avai labl e and we are i n the proces s of obtaini ng a br eedi ng pair fr om The Jac ks on Laborat or y.
KEY RESEARCH ACCOMPLISHMENTS
• Very early data support our prediction that tumorigenic 4T1 breast cancer cells grow more rapidly in mice depleted of γδ-T cells. However, as noted above, we are currently optimizing our model by downwardly titrating the number of 4T1 cells used to establish tumors. Also, we will no longer use the commercially available GL3 antibody to deplete mice of γδ-T cells on account of cost. We are now purifying our own GL3 using a hybridoma obtained from a colleague.
• Immunotherapy studies in the syngeneic mouse model at this point are inconclusive as we have not been able to reliably generate the larger numbers of γδ-T cells needed for the larger studies. This problem is being directly addressed by the purchase of αβ -T cell defi c ient mous e on the BALB/ c bac kground whic h wi l l then serv e as our s our ce of γ δ-T cell s f or our st udi es .
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